Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluoroquinolone-Based Regimens for Uncomplicated Brucellosis
NCT07887126Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Shihezi University
- Start
- Nov 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Randomised, open-label trial of levofloxacin and moxifloxacin in brucellosis (3 arms), sponsored by The First Affiliated Hospital of Shihezi University. Primary endpoint: Clinical and microbiological composite cure rate at 6 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
levofloxacinmoxifloxacin
03
Conditions
brucellosis
Beyond the preview
Go deeper on NCT07887126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07887126.